Ibotinib medical insurance ratio

Legal analysis: Compared with the average retail price, the price of 17 drugs for negotiation decreased by 56.7% on average. Among them, there are 9 varieties with a decrease of more than 65%, including: acitinib, crizotinib, sunitinib, oxitinib, nilotinib, pasopani, celetinib, cetuximab and ibrtinib. The negotiated payment standard of most imported drugs is lower than the market price of neighboring countries or regions, with an average of 36% lower. "This negotiation is very difficult. For many years, China government has been negotiating with foreign pharmaceutical companies on patented drugs, especially new drugs. Previously, the industry expected that the decline would reach about 40%, and now the average decline is over 50%. This result is very encouraging.

Legal basis: People's Republic of China (PRC) Social Insurance Law.

Article 2 The state establishes social insurance systems such as basic old-age insurance, basic medical insurance, industrial injury insurance, unemployment insurance and maternity insurance, so as to guarantee citizens' right to receive material assistance from the state and society in accordance with the law in case of old age, illness, industrial injury, unemployment and maternity.

Twenty-sixth basic medical insurance for employees, new rural cooperative medical care and basic medical insurance for urban residents shall be implemented in accordance with state regulations.

Twenty-eighth medical expenses that meet the basic medical insurance drug list, diagnosis and treatment items, medical service facilities standards and emergency treatment and rescue shall be paid by the basic medical insurance fund in accordance with state regulations.